secwatch.observer — SEC 8-K summary
======================================

Issuer:     OSR Holdings, Inc. (OSRH)
CIK:        0001840425
Form:       8-K
Filed at:   2026-10-28T13:30:13+00:00
Accession:  0001213900-26-113126
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Nasdaq panel denies OSR Health appeal, orders delisting; stock now quoted OTC as OSRH
--------------------------------------------------------------------------------

- Panel decision dated Oct. 23, 2026 follows the Aug. 26, 2026 suspension of OSRH and OSRHW for failing Nasdaq's $1.00 minimum bid price rule.
- Company says it chose not to pursue a reverse stock split and will detail its plan to regain a national exchange listing on or before Nov. 6, 2026.
- $15 million equity put option with BCM Europe AG under the VXM01 license remains in place; as amended Oct. 15, 2026 it can settle via convertible notes at roughly $2.00-$5.00 per share.
- Shareholder Loyalty CVR Program to continue, with the CVR Agreement to be amended so price thresholds are measured on whatever market the stock then trades on.
- Pipeline: Vaximm preparing publication of Phase 2a glioblastoma data for VXM01; Darnatein in licensing talks; Woori IO glucose monitoring draws global partnership interest.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840425/000121390026113126/0001213900-26-113126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840425/000121390026113126/ea0309929-8k_osrhealth.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-113126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer